MS Comprehensive Cancer Care Coalition Task force; create.
House Bill 1498 creates the Mississippi Comprehensive Cancer Care Coalition (MCCCC) Task Force to develop a statewide plan for addressing cancer-related issues. The task force is directed to examine the full cancer control continuum, including primary prevention, early detection, diagnosis, treatment, and survivorship, and to do so with an emphasis on health equity, data-driven goals, and alignment with CDC cancer prevention guidance and National Comprehensive Cancer Network guidelines.
The bill establishes a broad, multi-sector membership that includes legislators, state health and insurance officials, Medicaid, pharmacy and hospital representatives, oncology physicians, health plans, Blue Cross & Blue Shield of Mississippi, PhRMA, cancer advocacy organizations, cancer survivors, and a hospice provider. The task force must be appointed promptly after enactment, meet at least quarterly, and submit its plan and any recommended legislation to the Legislature by December 1, 2025, at which point it dissolves.
The bill does not directly change substantive cancer-care statutes or create new regulatory requirements for providers or insurers. Instead, it creates a temporary advisory task force within state government, requires the Department of Health to provide staff support, and authorizes state agencies and political subdivisions to supply information, facilities, and assistance upon request. Its practical effect is to generate policy recommendations and potentially future legislation on cancer care, access, and disparities in Mississippi.
The available voting history shows strong support in the House, with passage by a 118-0 vote. No committee transcript is available, but the unanimous vote suggests broad bipartisan agreement and little visible opposition to the concept of creating a cancer-care planning task force. The bill’s framing around cancer treatment, survivorship, and health equity likely contributed to its favorable reception.
There is no recorded floor or committee debate in the provided materials, so no specific objections are documented. Potential areas of policy tension, based on the bill’s structure, could include the inclusion of industry and insurer representatives alongside patient advocates and survivors, as well as the possibility that the task force’s recommendations could lead to future changes in Medicaid, insurance coverage, or cancer-care policy. However, no opposition is reflected in the vote or available discussion.